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Abstract
Background: Circulating CD34+ progenitor cells have the potential to differentiate into a variety of cells, including 
endothelial cells. Knowledge is still scarce about the transcriptional programs used by CD34+ cells from peripheral 
blood, and how these are affected in coronary artery disease (CAD) patients.
Results: We performed a whole genome transcriptome analysis of CD34+ cells, CD4+ T cells, CD14+ monocytes, and 
macrophages from 12 patients with CAD and 11 matched controls. CD34+ cells, compared to other mononuclear cells 
from the same individuals, showed high levels of KRAB box transcription factors, known to be involved in gene 
silencing. This correlated with high expression levels in CD34+ cells for the progenitor markers HOXA5 and HOXA9, 
which are known to control expression of KRAB factor genes. The comparison of expression profiles of CD34+ cells 
from CAD patients and controls revealed a less naïve phenotype in patients' CD34+ cells, with increased expression of 
genes from the Mitogen Activated Kinase network and a lowered expression of a panel of histone genes, reaching 
levels comparable to that in more differentiated circulating cells. Furthermore, we observed a reduced expression of 
several genes involved in CXCR4-signaling and migration to SDF1/CXCL12.
Conclusions: The altered gene expression profile of CD34+ cells in CAD patients was related to activation/
differentiation by a retinoic acid-induced differentiation program. These results suggest that circulating CD34+ cells in 
CAD patients are programmed by retinoic acid, leading to a reduced capacity to migrate to ischemic tissues.
Background
CD34+ progenitor cells reside in the bone marrow, and
are able to differentiate into mature monocytes, granulo-
cytes, T cells and B cells and endothelial cells. Their mul-
tipotential and migratory capacity also enables them to
circulate in peripheral blood. Local signals from dam-
aged, ischemic peripheral tissue may provide signals that
induce differentiation to cell types that support regenera-
tion of damaged tissue by angiogenesis, myogenesis and
neurogenesis. Bone marrow-derived cells expressing
CXCR4 are required for neovascularization, secreting
factors such as MMP9, and disappear again after oxygen
saturation is normalized [1]. Hypoxia induces HIF1a,
VEGF and SDF-1, leading to the attraction of hematopoi-
etic precursor cells, which provide a local microenviron-
ment nurturing neovascularisation and neurogenesis
[2,3]. Likewise, circulating endothelial precursor cells
(EPC) may help tissue repair and angiogenesis by recruit-
ing local mature endothelial cells [4].
In the last decennium, autologous bone marrow-, or
peripheral blood derived progenitor cells have been used
for intracoronary injection to repair ischemic cardiac tis-
sue after acute myocardial infarction, with contradictory
outcomes and overall limited success [5,6]. Aside from
technical issues regarding isolation protocols, the func-
tional capacity of autologous stem cells may not be opti-
mal and may differ among patients with coronary artery
disease (CAD).
Apart from their regenerative capacities via angiogene-
sis and myogenesis, progenitor cells are also believed to
be involved in the initiation and development of athero-
sclerotic disease. A low number of peripheral blood
CD34+/KDR+ cells is associated with increased cardio-
vascular events in a group of patients with CAD [7]. Sim-
ilarly, decreased levels of circulating progenitor cells
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(CD34+KDR+) were shown to be correlated to increased
subclinical atherosclerosis [8]. A recent study has pre-
sented evidence of a genetic regulation of EPCs in athero-
sclerosis [9].
A detailed, genome-wide description of the characteris-
tics of circulating progenitor cells in patients with athero-
sclerotic disease is currently lacking. This is important
knowledge and would be a first step to improve the suc-
cess rate of autologous progenitor cell transplantation
after myocardial infarction. Also, the comparison of the
transcriptome of progenitor cells from patients with CAD
versus healthy controls might give insights into the role of
these cells in the development of atherosclerosis.
In the present study we performed such a genome-wide
transcriptome analysis for the first time, presenting a
clear signature of circulating progenitor cells. The results
indicate that CD34+ cells from patients with CAD have
acquired a retinoic acid-induced signature with a low
migratory profile, potentially associated with impaired
endothelial repair.
Results
Patient characteristics and transcriptome analysis of 
circulating cells
23 patients suspected of significant CAD were referred to
the catheterization laboratory. Based on the coronary
angiography we selected 12 patients with severe coronary
atherosclerosis and 11 well-matched controls without
atherosclerotic coronary lesions, further referred to as
"controls" [10]. All patients were on aspirin and statin
treatment. Baseline characteristics did not differ between
atherosclerotic patients and controls except for lipopro-
tein (a) [10]. The atherosclerotic patient group showed
enhanced serum levels of the atherosclerosis marker
sICAM, supportive for the vascular inflammatory disease
status of these patients, despite medication taken. In
CAD patients versus controls, we found no differences in
numbers of circulating mononuclear cells, monocytes,
lymphocytes, and CD34+ progenitor cells (4.3 ± 1.2 ver-
sus 3.7 ± 0.7/μl; p = 0.7), as measured in flow cytometry
[10]. The Due to the low circulating numbers, purity of
isolated CD34+ cells was generally around 75% in both
CAD patients and controls, whereas purity of the other
mononuclear cells was >90% [10]. Gene expression analy-
sis for all cell types was performed on Illumina® beadchip
microarrays, which proved to be highly reproducible as
indicated by very low inter-sample variation among tech-
nical replicates (as described before [10]). Despite very
low numbers of circulating CD34+ cells we were able to
isolate sufficient amounts of RNA from all 23 patients to
perform microarray hybridizations. An unsupervised
hierarchical clustering of the complete transcriptomes
discriminated all different cell types with high specificity,
clearly discriminating the highly reproducible transcrip-
tomes of the CD34+ cells from the other mononuclear
cells (see additional file 1: Figure S1).
The transcriptome of CD34+ cells
A paired analysis in Significance Analysis of Microarrays
(SAM) [11] was performed on the transcriptome of
C D 3 4 +  c e l l s  c o m p a r e d  t o  t h e  t r a n s c r i p t o m e  o f  C D 4 +
cells, CD14+ cells and CD14+ macrophages from the
same individuals (n = 23) [10]. At a false significance rate
of 5%, we identified 2458 genes that showed high expres-
sion in CD34+ cells compared to each of the other cell
types, while 1891 genes were expressed at lower levels in
the CD34+ cells, visualized by one-way hierarchical clus-
tering in Figure 1. A comparison of our adult CD34+ cell
expression profile to that of cord blood-derived CD34+
cells as described by Hemmoranta [12] revealed that the
majority of the genes assigned with a HUGO symbol that
were expressed in CD34+ cells and not in CD133+ cells,
were also expressed in our adult blood CD34+ population
(66% n = 71). Although the data cannot be directly com-
pared due to the different platforms used, they suggest a
Figure 1 Differentially expressed genes in CD34+ cells compared 
to more differentiated cells. Visualization of expression of 2518 
genes that were more highly expressed in CD34+ cells (A), and 1867 
genes that were expressed at lower levels (B) compared to each of the 
three other cell types (indicated at the top). Genes were identified by a 
pairwise comparison of CD34+ cells with each of the other 3 cell types 
in 23 individuals. Red indicates a high level of expression, green a low 
expression level, and black indicates intermediate expression
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large overlap in expressed genes in CD34+ cells irrespec-
tive of age.
Gene ontology analysis using the PANTHER database
of protein families was used to classify enriched genes of
either higher or of lower expression in CD34+ cells (Fig-
ure 1, Table 1 and 2). The "apoptosis signaling pathway" is
reduced in CD34+ cells. These genes include anti-apop-
totic genes, but predominantly pro-apoptotic genes, sug-
gesting a pro-survival status. A list of the apoptotic
pathway genes is provided in additional file 2: Table S1.
Analysis of the more highly expressed genes revealed a
significant enrichment of genes encoding for nucleic acid
binding proteins in CD34+ cells (p = 1.4 × 10-24, Table 1),
being predominantly of the Zinc finger family with a
KRAB domain (129 members were present among the
CD34-specific genes). Next, we compared the list of
KRAB factor genes to curated genesets in the Molecular
Signatures Database (MSigDB) [13], showing substantial
overlap with genes that can be induced by the homeodo-
main containing protein HOXA5 [14]. Furthermore, this
set partly overlapped with a series of 10 KRAB factors,
identified to be expressed in human CD34+ cells (gene
set contributed by Jean-Pierre Bourquin, Dana-Farber
Cancer Institute, Boston, USA, unpublished results, Table
3). Significantly, all but 1 of the measurable HOX genes,
essential for stem cell self renewal and pluripotency were
expressed at significantly higher levels in CD34+ cells
with HOXA5 and HOXA9 being most strongly overex-
pressed (Table 4).
The CD34+ cell transcriptome of CAD patients indicates a 
more differentiated phenotype
A two-class statistical analysis in SAM (false discovery
rate < 5%) of CD34+ cells identified 303 genes that were
expressed at higher levels in CAD patients versus con-
trols, while 405 genes were expressed at lower levels in
the CAD patients. A one-way cluster analysis was per-
formed to visualize the correlation of expression of the
significant differentially expressed genes, represented in
Figure 2A. For a biological interpretation of the differen-
tially expressed genes, we performed a gene ontology
Table 1: Gene ontology analysis of genes expressed at higher levels in CD34+ cells
Molecular Function # genes p-value
Nucleic acid binding 440 1.41E-24
Transcription factor 328 6.13E-20
Zinc finger transcription factor 173 3.54E-16
KRAB box transcription factor 129 4.95E-16
Synthase and synthetase 63 1.93E-13
Transferase 154 1.13E-11
Synthase 37 1.97E-09
Methyltransferase 34 5.45E-05
Oxidoreductase 93 9.25E-05
Hydrolase 105 5.66E-04
Lyase 32 1.23E-03
Kinase 97 1.43E-03
Transcription cofactor 35 2.58E-03
Synthetase 24 3.41E-03
Other miscellaneous function protein 68 3.98E-03
Nuclease 36 1.19E-02
DNA-directed DNA polymerase 10 1.30E-02
Translation initiation factor 17 1.81E-02
Select regulatory molecule 145 2.39E-02
DNA helicase 19 2.91E-02
Acetyltransferase 20 2.99E-02
Ligase 65 3.82E-02
Aminoacyl-tRNA synthetase 12 3.89E-02
Molecular functions of genes which are upregulated in CD34+ cells compared to more differentiated hematopoietic cells (no significant 
pathways were identified).van der Pouw Kraan et al. BMC Genomics 2010, 11:388
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analysis in the Panther database and categorized the
genes with a specific molecular function or biological
process (Figure 2B).
The genes expressed at higher levels in CAD patients
display a quite homogenous expression pattern across the
different patients and controls, with an average fold
change in expression of 1.5. The set of 303 genes which
were upregulated in CAD patients was enriched for genes
with nucleic acid binding properties and 11 genes
involved in the "MAPKKK cascade", including
MAP3K12/MUK, MAPK11/p38 beta, MAPK12/p38-
gamma, and MAPK7/ERK5 and 60 genes involved in
"Nucleoside, nucleotide and nucleic acid metabolism",
including transcription factors, DNA- and RNA heli-
cases, RNA polymerases and mRNA splicing factors, sug-
gesting a higher transcriptional activity.
The genes expressed at lower levels in CAD patients
display more interindividual variation between patients
and controls with an average fold difference in gene
expression of -2.4.
A set of 19 genes were enriched in the "histone" cate-
gory. Of these 19 histone genes that were expressed at
lower levels in CD34+ cells from CAD patients, 13 were
enriched in CD34+ cells compared to more differentiated
cells (Figure 1). We included 2 representative examples in
Figure 3A and 3B. A more detailed analysis showed that 8
of the 19 histone genes that were downregulated in CAD
patients' CD34+ cells in our study belonged to the most
undifferentiated hematopoietic stem cells (HSC) tran-
scriptome as identified by Georgantas et al [15]. This
HSC-specific gene set was generated from a comparison
of the transcriptomes of CD34+/CD38-/Lin- (HSC-
Table 2: Gene ontology analysis of genes expressed at lower levels in CD34+ cells
Molecular Function # genes P-value
Membrane traffic protein 63 2.40E-13
Nucleic acid binding 280 4.89E-09
Select regulatory molecule 137 4.40E-07
Vesicle coat protein 16 1.53E-05
Chaperone 33 2.31E-05
Other chaperones 21 2.55E-05
Other transcription factor 50 3.29E-04
Ligase 59 6.84E-04
Miscellaneous function 95 7.58E-04
Ubiquitin-protein ligase 36 4.15E-03
Transporter 69 1.61E-02
Phosphatase 34 2.13E-02
Other RNA-binding protein 29 2.35E-02
mRNA processing factor 24 2.80E-02
Transferase 87 3.26E-02
G-protein modulator 49 4.85E-02
Other transporter 42 4.89E-02
Pathway # genes P-value
Apoptosis signaling pathway 36 3.02E-09
Ubiquitin proteasome pathway 22 1.34E-04
Huntington disease 28 1.10E-02
Ras Pathway 18 2.17E-02
Transcription regulation by bZIP 
transcription factor
17 3.32E-02
PDGF signaling pathway 28 4.99E-02
Molecular functions and pathways represented by genes expressed at lower levels in CD34+ cells, compared to more differentiated 
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enriched)  versus  CD34+/[CD38/Lin]++ cells (HPC-
enriched, HSC-depleted) from normal human adult
donor bone marrow, neonatal placental/umbilical cord
blood, and mobilized adult donor peripheral blood stem-
progenitor cells [15].
An unsupervised cluster analysis of the HSC-specific
genes from our CD34+ cells divided most patients and
controls in separate branches (Figure 3C, Fisher exact, p =
0.04), indicating that CD34+ cells from CAD patients
showed a more differentiated profile than CD34+ cells
from controls. Because EPCs were earlier shown to corre-
Table 3: KRAB factors enriched in CD34+ cells are regulated by HOXA5
KRAB factor Human CD34-enriched TF p = 5.31E-07 HOXA5 Targets p = 1.26E-05
ZNF165 + +
ZNF14 + +
ZNF228 + +
ZNF22 +
ZNF282 +
ZNF187 +
ZNF175 +
ZNF212 +
ZNF167 +
ZNF324 +
ZNF435 +
ZNF136 +
ZNF195 +
ZNF3 +
ZNF20 +
ZNF426 +
Part of the CD34-enriched KRAB domain transcription factors overlap with previously identified transcription factors in CD34+ cells, and 
HOXA5 target genes. A comparison of CD34-enriched KRAB factors with curated genesets was performed in the MSig database [13]. TF; 
transcription factors
Table 4: Expression of HOX genes is enriched in CD34+ cells.
CD34 CD14 Macrophages CD4 average
avg expr avg expr q-value avg expr q-value avg expr q-value Fold 
Change
HOXA5 2117 12 0.0 12 0.0 7 0.0 279.1
H O X A 9 1 0 7 3 3 00 . 01 80 . 01 00 . 0 7 6 . 7
HOXB5 266 19 0.0 18 0.0 18 0.0 16.6
HOXA3 92 7 0.0 7 0.0 7 0.0 15.2
HOXA10 96 12 0.0 11 0.0 10 0.0 9.4
HOXC4 173 23 0.0 24 0.0 37 0.0 7.4
H O X B 4 8 31 40 . 01 20 . 05 50 . 05 . 6
HOXA6 213 77 0.0 63 0.0 82 0.0 3.6
HOXB2 301 131 0.0 202 0.0 752 0.0 1.6
HOXC13 115 186 0.0 204 0.0 137 1.2 -1.3
The average transcript expression level of the individual HOX genes is shown for each cell type. q-values indicate the significance of 
differential expression compared to CD34+ cells (generated by SAM[11]). The last column indicates the average fold change of the expression 
of HOX genes in CD34+ cells compared to each of the other cell types, in a paired analysis (23 pairs, and 3 comparisons).van der Pouw Kraan et al. BMC Genomics 2010, 11:388
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late with cardiovascular end points, markers of the
endothelial lineage (von Willebrand factor and CD133/
PROM1) were tested in the CD34+ progenitor cells in
this study. Although both markers were expressed at sig-
nificantly higher levels in the CD34+ versus other mono-
nuclear cell types, their levels did not vary between our
control and CAD patient groups.
The gene expression profile of CD34+ cells from CAD 
patients correlates with a RA-induced profile
Because the 303 genes with a higher expression in CAD
patients showed a highly correlated profile, suggesting a
common inducer of this profile, we set out to analyze
whether we could find genes/transcription factors that
could be causal for this profile by searching for the genes
that best represent this cluster. For this purpose we calcu-
lated the average expression of the 303 genes in each indi-
vidual patient and control, and subsequently identified
genes from the complete data set of all 8943 expressed
genes in CD34+ cells that correlated best with this aver-
age profile. Interestingly, among the top 12 best correlat-
ing genes with this profile in CD34+ cells was the
transcriptional regulator RAI1, (Retinoic acid-induced 1,
R = 0.91, Figure 4A). RAI1 was also expressed at signifi-
cantly higher levels in CAD patients (FDR = 4.3%), and
indeed is located in the middle of the 303 gene cluster in
Figure 2. The other genes which showed a good correla-
tion with the average profile of 303 genes could not be
tracked back to a specific transcription factor or other
factor which may be causal for increased gene expression.
Because Retinoic acid (RA) is a well known modulator of
stem cell differentiation, we next focused on genes that
are involved in RA-signaling. We identified three RA-
related genes that showed a highly correlated expression
with RAI1, but did not reach statistical significance in the
SAM list of 303 genes at an FDR of 5%. Two of them are
known to be induced by RA; RAI16 (retinoic acid
induced 16, R = 0.84, p < 0.0001), and ZNF42 (zinc finger
protein 42, myeloid-specific retinoic acid-responsive, R =
0.80 p < 0.0001) and its receptor RARα2 (retinoic acid
receptor, alpha, transcript variant 2, R = 0.68, p = 0.0003).
The combined expression values of all 4 genes also
showed a high correlation coefficient (R = 0.91, p <
0.0001) with the average expression of the 303 genes
expressed at higher levels in CAD patients (R = 0.91, p <
0.0001, data not shown), which is suggestive for a causal
role of RARα stimulation by its ligand, all-trans retinoic
acid, in the upregulation of genes in CD34+ cells in CAD
patients.
To confirm that the analysis of genes which correlate
with RAI1 is related to retinoic acid exposure, we also
subjected all genes which showed a positive correlation
with RAI1 (R > 0.60, 1304 genes, including 75% of the 303
significant genes) to a pathway analysis in Metacore™. In
this case the most significant pathway was "Ligand-
Dependent Transcription of Retinoid-Target genes" (p = 2
× 10-4), indicating that RAI1 is a good marker for RA-
induced transcriptional change. Next, we compared the
expression of RAI1 in CD34+ cells from CAD patients
and controls to the different peripheral blood cell types,
depicted in Figure 4B. Increased expression of RAI1 is
restricted to CD34+ cells from CAD patients, suggesting
an actively induced expression.
The CD34+ cell transcriptome of CAD patients indicates a 
compromised migratory capacity
Next to the gene ontology analysis, we also performed an
analysis in Metacore™ systems biology suite, which
revealed a reduced migratory capacity in CD34+ cells
f r o m  C A D  p a t i e n t s  ( a d d i t i o n a l  f i l e  3 :  F i g u r e  S 2 ) .  T o
search for a possible relation to RA, we performed a path-
way mapping analysis in Metacore™ on genes which were
negatively correlated with RAI1 (R < -0.60, 460 genes).
The most significant pathway, represented by these genes
was "Chemotaxis/CXCR4 signaling pathway" (p = 2 × 10-
6). These results suggest that RA may indeed have down-
regulated the genes involved in adhesion and migration.
CXCR4 signal transduction depends on the activity of
small GTPases [16]. We identified a reduced expression
of this protein family, including guanine nucleotide bind-
ing protein (G protein), alpha z polypeptide (GNAZ, Fold
Change, FC = -5.41), GNB5, FC = -4.22, GNG11, FC = -
4.36, and GNG8, FC = -11.36. The categories "cytoskele-
ton protein", and "cell structure and motility" represented
by genes with low transcript levels, indicate that the more
downstream effector genes of CXCR4 signaling were also
expressed at lower levels. These include cell division cycle
42 (CDC42), a small GTPase of the Rho-subfamily (FC =
Figure 2 CD34+ cells from CAD patients show an altered gene ex-
pression profile. Visualization of the expression of 708 genes with sig-
nificantly different expression levels in CD34+ cells from CAD patients 
compared to controls.
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-2.1) (Figure 5), important for migration and adhesion,
and other genes in the Rho/cytoskeleton pathway: myosin
light chain (MYL) 9 (FC = -11.7), MYL6 (FC = -1.4) and
myosin light chain kinase, MYLK (FC = -4.9). (see addi-
tional file 4: Figure S3). Migratory and adhesive function
may also be affected by the lower expression of the integ-
rins: fibronectin receptor beta/integrin beta 1 (ITGB1, FC
= -3.2) and ITGB5 (FC = -6.6), and the tetraspanins CD9
Figure 3 CD34+ cells from CAD patients are less primitive. Histone gene expression is decreased in CD34+ cells from CAD patients. mRNA expres-
sion levels are shown of two representative histone genes, HIST1H3H (A) and HIST1H2AG (B) in all studied cell types in CAD patients (squares) and 
controls (triangles). C: Several histone genes belong to the more "primitive" HSC genes [15] and are expressed at lower levels in CD34+ cells from CAD 
patients.
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Figure 4 A retinoic acid-induced signature in CD34+ cells from CAD patients. A. The induced signature in CD34+ cells from CAD patients corre-
lates with the expression of RAI1. The average expression of the 303 genes of the induced signature of CAD patients is plotted against the expression 
of RAI1 (CAD patients are represented by squares, controls by triangles). B. Retinoic acid-induced 1 gene expression in different cell types in CAD pa-
tients and controls. C. The expression of RAI1 is shown for all studied cell types in CAD patients (squares) and controls (triangles).
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(FC = -2.3) and CD151 (FC = -4.4). (see additional file 3:
Figure S2).
Discussion
In this study, we generated a CD34+ cell-enriched tran-
scriptome from a pair-wise comparison of the gene
expression profiles from peripheral blood CD34+ cells
with those from other common differentiated
hematopoietic mononuclear cells from the same individ-
ual. Almost all previous profiling studies on CD34+ cells
were focused on bone marrow-derived cells, or G-CSF-
mobilized CD34+ cells from peripheral blood. A paired
transcriptome analysis of adult CD34+ cells with other
blood cell types has not been performed before, and
Figure 5 The CXCR4 pathway is affected in CD34+ cells from CAD patients. Genes with a lower expression in CD34+ cells from CAD patients rep-
resent the Chemotaxis CXCR4 signaling pathway (P = 2.1 × 10-3). Genes expressed at significantly lower levels are indicated by a red arrow and are 
encircled for clarity.
Chemotaxis/CXCR4 signaling pathwayvan der Pouw Kraan et al. BMC Genomics 2010, 11:388
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allowed us to identify the transcriptome of CD34+ cells
without the influence of interindividual genetic and envi-
ronmental differences. In addition, a comparison of the
CD34+ cell transcriptome from CAD patients with that
of controls identified differentiation characteristics and
reduced migratory/adhesive capacity of CD34+ cells
from the patient group, related to a retinoic acid-induced
program.
To the best of our knowledge, this is the first report on
the highly significant increased expression of the zinc fin-
ger KRAB domain-containing transcription factors in cir-
culating CD34+ cells (129 in total). This relatively novel
family of transcription factors is thought to mediate sup-
pression of transcription. The specific function of many
KRAB factors is still unknown, but inhibition of RNA
polymerase I, II, and III promoters and RNA splicing has
been reviewed [17]. Recently, it has been suggested that
the repressor complex, containing KAP1, may autoregu-
l a t e  t h e  e x p r e s s i o n  o f  t h e  K R A B - Z N F  f a m i l y  [ 1 8 ] .  A
model has been proposed in which the zinc finger
domains determine the specificity of DNA binding, while
the KRAB domain binds to KAP1 (KRAB-associated pro-
tein 1), which recruits chromatin remodeling proteins
that cause the formation of heterochromatin (condensed
inactive DNA) and thus gene silencing [17]. The expres-
sion of KAP1 was also significantly higher in CD34+ cells
than in the other cell types (data not shown). Thus, our
data indicate a specific molecular signaling pathway by
which CD34+ precursor cells are kept in a quiescent state
compared to other peripheral blood mononuclear cells.
From the comparison of the CD34+ gene set with curated
gene sets in the MSig database [13], it became clear that
there was a significant overlap of several KRAB factors
expressed in CD34+ cells and in cells with HOX (homeo-
box) A5 overexpression [14]. Indeed we identified a high
expression of HOXA5 transcripts in CD34+ precursor
cells, which could therefore explain the expression of a
subset of the KRAB factors. Based on their similarity in
protein structure, the eight other HOX genes that were
enriched in CD34+ cells may possibly regulate the
expression of other subsets of KRAB-ZNF transcription
factors. There are 39 members of the HOX gene family in
the mammalian genome. These homeobox genes encode
for proteins with a helix-turn-helix motif (the homeo
domain), which binds to specific sequences of DNA,
allowing them to function as transcription factors,
important during embryonic development, but also
throughout life in lineage-specific cell differentiation
from precursor cells [19]. Most of their functions have
been assigned through over- or under expression and
include both self-renewal, and differentiation towards
several hematopoietic cell types [19]. The expression of
HOXA9 is particularly important for differentiation into
endothelial precursor cells (EPC) [20]. In this study, the
expression of all but one of the measurable HOX genes
was CD34-enriched, consistent with their differentiation
potential.
We compared the transcriptome of CD34+ cells from
CAD patients to accurately matched controls, with iden-
tical medication (a comparison of the other cell types is
reported elsewhere [10]). Although the number of circu-
lating CD34+ cells between CAD patients and controls
did not differ, consistent with the previously reported
lack of association of CD34+ cell counts with carotid
intima-media thickness [8], the transcriptome did show
marked differences. We identified lower transcript levels
o f  h i s t o n e  e n c o d i n g  g e n e s  i n  C D 3 4 +  c e l l s  f r o m  C A D
patients. This is remarkable because histone encoding
genes are typically expressed in early HSC, suggesting a
shift towards a more differentiated phenotype of CD34+
cells in CAD patients [15]. These results would imply that
CD34+ cells in CAD patients have been pre-activated in-
vivo. Corresponding with an activated phenotype, we
observed a higher expression of several members of the
MAPkinase family in CAD CD34+ cells. The role of an
activated MAP kinase pathway in CAD patients is hith-
erto unknown. MAP kinases are regulated by a broad
range of environmental stimuli, such as growth factors
and stress (reviewed in [21]). A downstream target of all
of the upregulated MAP kinases (ERK5 (MAPK7), p38β
(MAPK11), and p38γ (MAPK12)), is the transcription
factor Myocyte Enhancer 2 (MEF2), which positively reg-
ulates target gene transcription (reviewed in [22]).
Although the role of MEF2 in CD34+ cells is unknown,
MEF2 has been implicated as an important regulator of
muscle, neuronal and immune cell function and differen-
tiation [22]. We identified 11 members of the KRAB box
transcription factors expressed at higher levels in the
CD34+ cells from CAD patients and 4 apoptosis-related
genes were expressed at lower levels. However, the num-
ber of genes was too low to reach statistical significance
in a pathway level analysis.
Detailed analysis of the genes with a lower expression
in CD34+ cells from CAD patients led us to conclude that
signaling and migration through CXCR4 may be affected.
SDF-1/CXCL12, the ligand for CXCR4, is the predomi-
nant chemotactic and retention factor for stem cells. The
capacity of bone marrow-derived mononuclear cells to
repair ischemic tissue by revascularization therefore criti-
cally depends on their expression of CXCR4 [23]. EPC
from CAD patients were shown to have a reduced revas-
cularization capacity, with diminished CXCR4 signaling,
as Jak2 phosphorylation by CXCL12 is impaired, com-
pared to EPC from healthy individuals, while the expres-
sion levels of CXCR4 are normal [24]. In this study, no
difference in CXCR4 mRNA expression in CD34+ cells
from CAD patients was observed. However, lower tran-
script levels of genes were found involved in signal trans-van der Pouw Kraan et al. BMC Genomics 2010, 11:388
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duction and effector functions of CXCR4, i.e. G proteins
(several small GTPases), actin filament assembly, (includ-
ing CDC42), and binding capacity (integrins and tetrasp-
anins). CDC42 has been discovered as an important
regulator of stem cell migration through CXCR4 signal-
ing [25]. Therefore, the migratory capacity of CD34+ cells
from CAD patients appears affected in signaling, as well
as cytoskeleton rearrangements and adhesive properties.
The more activated phenotype and reduced migratory
capacity of CD34+ in CAD patients may be explained by
an in vivo activation by retinoic acid. All-trans retinoic
acid (atRA), the active vitamin A metabolite, regulates
the growth and differentiation of a variety of cell types
and tissues including stem cells and neuronal tissues. RA
is known to activate ERK5 (MAPK7), suggesting that the
increased expression of ERK5 (MAPK7) in CD34+ cells
from CAD patients may be related to an increased sensi-
tivity to RA [26]. The transcript levels of the MAPK path-
way correlated with the RA-induced genes, including
RARα2, supportive for a causal relationship between RA
and MAPK activation (Figure 4C, R = 0.66). Interestingly,
during RA-induced neurogenesis, MAPkinase p38 acti-
vates MEF2 [27], providing a direct link between RA,
MAPkinases, MEF2 activation, and differentiation.
The most significant upregulated RA-inducible gene in
CD34+ cells from CAD patients was RAI1, a transcrip-
tion factor which does not posses a DNA binding domain
but likely influences differentiation through complex for-
mation with other proteins mediating chromatin remod-
eling [28]. The increased expression of the RARα may
contribute to RA responsiveness in CD34+ cells from
CAD patients. In correspondence with an RA-induced
profile in CD34+ cells from CAD patients, these cells
showed a concomitant higher expression of the transcrip-
tion factor GATA2, which has been reported to function-
ally cooperate with RARα in embryonic stem cells [29].
The relevance of its increased transcription in CD34+
cells in CAD patients is underscored by the association of
a polymorphisms in GATA2 with familial early onset cor-
onary artery disease [30]. Interestingly, administration of
atRA in experimental nephritis diminishes migration of
PBMC to the site of inflammation. It was further demon-
strated that atRA inhibits cytoskeleton re-arrangements
required for cell morphology changes, cell adhesion and
migration [31]. These results, together with our observa-
tion that the genes involved in adhesion and migration
strongly anti-correlated with RAI1, suggest that RA may
have caused the low migratory profile in CD34+ cells
from CAD patients. It is unclear where the CD34+ cells
have received the activation signal from atRA. Measure-
ments of atRA in mouse and humans samples indicated
that concentrations are in the nanomolar range and are
m uc h highe r in t is s ues ( s uc h as  live r  sa m ples)  t ha n in
serum [32,33]. Most likely atRA is present at biologically
effective concentrations in the bone marrow, where
CD34+ cells reside before they enter the bloodstream.
CD34+ cells from bone marrow are responsive to atRA as
their cytokine-dependent growth is inhibited, while dif-
ferentiation is promoted by atRA [34]. The biological
effects of atRA are highly dependent on the differentia-
tion stage of the cell [35,36], which explains why only
CD34+ cells show signs of atRA activation, and none of
the more differentiated cell types.
Limitations
Patients were carefully matched for several parameters,
including medication and referall to a cardiologist.
Because all individuals were suspected of having coro-
nary artery disease, all were on aspirin and statin therapy.
However, the controls were free of visible coronary artery
disease at coronary angiography. Because the controls
had the same symptoms as patients with severe 3-vessel
CAD they may suffer from other underlying pathologies,
which may have masked our analysis. However, a control
group without symptoms would introduce a strong bias
through a lack of matching for medication and risk fac-
tors for atherosclerosis.
Because of our careful matching, the number of
patients and controls is limited. On the other hand, the
paired analysis of CD34+ cells with other cells from the
same individual strongly improves the power to detect
differences.
Conclusions
In general, hematopoietic progenitor cells may improve
tissue repair in ischemic conditions by providing a micro-
environmental niche allowing angiogenesis and neuro-
genesis from local more specific cell types [1-3]. The
reduced adhesive/migratory capacity of circulating pre-
cursor cells in CAD patients may restrict their recruit-
ment by CXCL12 to ischemic tissues, thereby limiting
their role in tissue repair. The data are supportive for a
causative role of retinoic acid in reducing the migratory
capacity. A role for retinoic acid in atherosclerosis has
been suggested by the identification of increased tran-
s c r i p t  l e v e l s  o f  t h e  r e t i n o i c  a c i d  r e c e p t o r  r e s p o n d e r - 1
gene (RARRES1) in unstable carotid endarterectomy
plaque specimens, suggesting that cells within atheroscle-
rotic plaques have been stimulated by retinoic acid [37].
Future research aimed at the functional consequences of
retinoic acid stimulation of CD34+ subpopulations and
isolated endothelial precursor cells could provide more
insight in the affected migration and differentiation of
precursor cells in CAD patients and ways to reverse this
programming. Collectively, our data suggest that the
capacities of precursor cells to support ischemic tissue
repair might be improved by counteracting the RA signa-van der Pouw Kraan et al. BMC Genomics 2010, 11:388
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ture, possibly by the development of an antagonist for the
RARα2 receptor.
Methods
Patient selection
This study is a substudy of a previously published investi-
gation [10]. It was approved by the institutional medical
ethics committee and has been performed in accordance
with the ethical standards laid down in the 1964 Declara-
tion of Helsinki. All patients gave informed consent prior
to their inclusion in the study. We selected 11 Caucasian
patients without any sign of CAD on a coronary angiog-
raphy. These patients are further referred to as "controls".
Controls underwent angiography because of symptoms
of chest pain and a high pretest-likelihood of atheroscle-
rotic CAD, justifying the invasive diagnostic procedure.
The controls were prospectively matched to 12 Caucasian
patients with severe triple-vessel CAD on the basis of age,
gender, race, smoking status, lipid-profile and medication
("atherosclerotic patients"). All patients and controls were
on aspirin and statin treatment. Exclusion criteria were:
myocardial infarction <4 weeks, diabetes mellitus, neo-
plastic disease and systemic inflammatory disease.
Statistical analysis
Fisher's exact test was used for testing association in 2 × 2
contingency tables. For single genes, comparisons among
the two groups were performed by Student's t-test and
when variances were different, a Welch's correction was
applied.
Isolation, culture and gene expression analysis of CD34+ 
cells
From all 23 patients and controls, 60 ml peripheral blood
was drawn from the arterial sheath after the angiography
but before possible coronary intervention. Using immu-
nomagnetic beads (Dynabeads, Invitrogen, Carlsbad,
CA), CD34+ precursor cells, CD14+ monocytes, and
CD4+ T cells were positively isolated for direct cell lysis,
while negatively isolated monocytes were taken into cul-
ture towards macrophages for 20 h. mRNA from all cell
populations was amplified and biotinylated using the Illu-
mina TotalPrep RNA amplification Kit (Ambion, Austin,
T X ) .  S i x  t e c h n i c a l  r e p l i c a t e s  w e r e  p e r f o r m e d .  F r o m
CD34+ cells we obtained sufficient amounts of mRNA for
one hybridization only. Samples were randomly hybrid-
ized to Sentrix HumanRef-8 Expression bead chip arrays
(Illumina, San Diego, CA), followed by scanning and fea-
ture extraction, performed at ServiceXS (Leiden, The
Netherlands), as previously described [10].
Analysis of gene array data
Normalization and statistical analysis of the gene array
bead summary data was carried out with established
methods using the limma package [38] and in-house
scripts in R/Bioconductor [39]. Bead summary intensities
were RMA-background corrected [40], log2-transformed
and normalized using quantile normalization [41]. For
the identification of over- or under-expressed genes in
CD34+ cells, we made three separate pair-wise compari-
sons between CD34+ cells and one of the other three cell
types (CD4+, CD14+, or CD14+-differentiated mac-
rophages) from the same individual (n = 23) in a two-
class paired analysis using Significance Analysis of
Microarrays (SAM) [11]. Because genes may be reliably
expressed in only one of the two mononuclear cell types
used in the comparisons, we included only genes in the
analysis if the average expression in at least one of the two
cell types was > 6 (Log2). Genes with a false discovery
rate (FDR) < 5% were considered significantly different.
Genes that consistently showed differential over- or
under expression between CD34+ versus all other cell
types were selected as CD34+ -enriched genes. For the
comparison of the CD34+ gene expression profiles
between CAD patients and controls we included genes
which showed an average log2 expression > 6, in a two-
class unpaired analysis in SAM.
Hierarchical clustering [42] of samples was used to
visualize the correlation of co-expressed genes in
Treeview (available at http://rana.lbl.gov/EisenSoft-
ware.htm).
For an interpretation of the biological processes that
are represented by the genes that show a significantly dif-
ferent level of expression in CD34+ cells, compared to the
other cell types, and for genes that differed in expression
between CAD patients and controls, we used Gene
Ontology analysis using the PANTHER (Protein ANaly-
sis  THrough  Evolutionary  Relationships) Classification
System at http://www.pantherdb.org/[43]. PANTHER
uses the binomial statistics tool to compare our gene list
to a reference list (NCBI: Homo sapiens genes) to deter-
mine the statistically significant over-representation of
functional groups of genes. A Bonferroni correction was
applied to adjust for multiple testing.
P values (Bonferroni-corrected) < 0.05 were considered
significant
Pathway analysis was performed by the Metacore™
m a p p i n g  t o o l s ,  d e v e l o p e d  b y  G e n e G o  ( G e n e G O ,  S t
Joseph, MI, http://www.genego.com/) .  D a t a  m i n i n g  i n
Metacore™ is based on a manually curated database of
human protein-protein, protein-DNA interactions, tran-
scription factors, signaling pathways and metabolic path-
ways. Calculation of statistical significance are based on
p-values which are defined as the probability of a given
number of genes from the input list to match a certain
number of genes in the maps. All microarray data have
been submitted to the Gene Expression Omnibus (GEO)
under accession number GSE9820.van der Pouw Kraan et al. BMC Genomics 2010, 11:388
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